Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Insulin Treatment in Cancer Cachexia

This study has been completed.
Swedish Cancer Foundation
Medical Research Council
Information provided by:
Göteborg University Identifier:
First received: May 23, 2006
Last updated: August 20, 2009
Last verified: August 2009
The study is designed to evaluate whether daily insulin treatment to weight losing cancer patients attenuates progression of cancer cachexia and improves metabolism.

Condition Intervention Phase
Cancer Cachexia
Drug: Insulatard, flexpen
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Insulin Treatment in Cancer Cachexia: Effects on Survival, Metabolism and Physical Functioning. A Randomized Prospective Study.

Resource links provided by NLM:

Further study details as provided by Göteborg University:

Primary Outcome Measures:
  • Health related quality of life,
  • food intake,
  • resting energy expenditure,
  • body composition,
  • metabolic efficiency,
  • spontaneous physical activity,
  • blood and hormonal tests
  • serum tumor markers

Secondary Outcome Measures:
  • Survival

Estimated Enrollment: 135
Study Start Date: January 2000
Study Completion Date: September 2005
Detailed Description:
Randomized study with long-term follow-up based on survival, health related quality of life, food intake, resting energy expenditure, body composition, exercise capacity and measurement of metabolic efficiency.

Ages Eligible for Study:   25 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Weight loss
  • Systemic solid cancer

Exclusion Criteria:

  • Diabetes
  • Brain metastases
  • Expectant survival of less than 6 months
  • Serum creatinine above 200 umol/l
  • Persistent of recurrent fever
  • Cholestasis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00329615

Department of Surgery, Inst of Clinical Sciences
Göteborg, Sweden, SE413 45
Sponsors and Collaborators
Göteborg University
Swedish Cancer Foundation
Medical Research Council
Principal Investigator: Kent G Lundholm, MD Department of Surgery, Göteborg University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00329615     History of Changes
Other Study ID Numbers: kl450112
Study First Received: May 23, 2006
Last Updated: August 20, 2009

Keywords provided by Göteborg University:
Cancer cachexia
Tumor host metabolism

Additional relevant MeSH terms:
Weight Loss
Body Weight Changes
Body Weight
Signs and Symptoms
Isophane Insulin, Human
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on April 28, 2017